Autolus Therapeutics plc - ADR
$2.33
$-0.11
(-4.51%)
As on 26-Aug-2026 16:00EDT
Market cap
$641 Mln
Revenue (TTM)
$117 Mln
P/E Ratio
--
P/B Ratio
8.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
266,162,540
9 Years Aggregate
CFO
$-691.78 Mln
EBITDA
$-867.83 Mln
Net Profit
$-854.23 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
| 17.1 | 60.7 | 37.1 | 45.6 | -9.9 | -18.7 | -- |
|
BSE Sensex*
| -8.7 | 1.7 | 1.8 | -4.3 | 6.0 | 6.7 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
| -15.3 | -63.2 | 238.9 | -63.4 | -41.9 | -32.3 | -59.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Autolus Therapeutics - ADR
|
2.3 | 641.5 | 117.4 | -280.0 | -197.9 | -221.4 | -- | 8.6 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 250.3 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Autolus Therapeutics - ADR
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product... consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Read more
-
CEO & Director
Dr. Christian Martin Itin Ph.D.
-
CEO & Director
Dr. Christian Martin Itin Ph.D.
-
Headquarters
London
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Autolus Therapeutics - ADR
What is the current share price of Autolus Therapeutics plc - ADR Today?
The share price of Autolus Therapeutics plc - ADR is $2.33 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Autolus Therapeutics plc - ADR has given a return of -9.94% in the last 3 years.
What is the current PB & PE ratio of Autolus Therapeutics plc - ADR?
Since, TTM earnings of Autolus Therapeutics plc - ADR is negative, P/E ratio is not available.
The P/B ratio of Autolus Therapeutics plc - ADR is 8.55 times as on 21-Aug-2026, a 60 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.84 |
2.97 |
2024 |
-2.83 |
1.46 |
2023 |
-5.38 |
10.05 |
2023 |
-1.95 |
3.64 |
2022 |
-1.50 |
0.75 |
What is the 52 Week High and Low of Autolus Therapeutics plc - ADR?
The 52-week high and low of Autolus Therapeutics plc - ADR are Rs 2.58 and Rs 1.18 as of 27-Aug-2026.
What is the market cap of Autolus Therapeutics plc - ADR?
Autolus Therapeutics plc - ADR has a market capitalisation of $ 641 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Autolus Therapeutics plc - ADR?
Before investing in Autolus Therapeutics plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.